mResvia’s prescribing information indicates that the vaccine was 78.7% effective at preventing RSV that presents with two or more symptoms at 3.7 months of follow-up – a little lower than ...

The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

Two AS01-adjuvanted vaccines for different pathogens -- the respiratory syncytial virus (RSV) vaccine (Arexvy) and the ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Arcutis is financially strong, with over 30 months of cash runway. The atopic dermatitis market is large and shifting away ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...

You can include Supplementary Information with your article to enhance and increase the impact of your work, for example by including 3D molecular models and movies. Authors can also improve the ...